Prostate Cancer Treatment Market to Reach USD 28.10 Billion by 2033 | Radioligand & Precision Oncology Advances Drive 7.8% CAGR

The Prostate Cancer Treatment Market size reached USD 13.22 billion in 2024 and is projected to reach USD 28.10 billion by 2033, growing at a CAGR of 7.8% from 2025 to 2033. This robust growth is driven by the rising global incidence of prostate cancer amid aging populations, advancements in targeted therapies like radioligand and immunotherapy, increasing early detection through improved diagnostics, expanding approvals for novel drugs addressing metastatic and castration-resistant forms, and growing investments in precision oncology and combination regimens.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-
https://www.datamintelligence.com/download-sample/prostate-cancer-treatment-market?sindhuri

North America: Key Industry Developments (Largest Region)
✅ November 2025: Johnson & Johnson acquired Halda Therapeutics for $3.05 billion, bolstering its prostate cancer pipeline with innovative "hold and kill" targeted therapies, including lead candidate HLD-0915.
✅ March 2025: Novartis expanded FDA approval for Pluvicto (177Lu-PSMA-617), enabling earlier use in PSMA-positive metastatic castration-resistant prostate cancer, delaying chemotherapy needs.
✅ February 2025: RedHill Biopharma initiated Phase II trials combining opaganib with darolutamide for metastatic castrate-resistant cases, targeting high-risk patients.

Asia Pacific: Key Industry Developments (Fastest Growing Region)
✅ November 2025: Regional awareness campaigns and diagnostic advancements accelerated adoption of targeted therapies in high-prevalence markets like Japan and India.
✅ October 2025: Government initiatives in China and India boosted funding for oncology infrastructure, facilitating access to advanced hormone and radioligand treatments.
✅ September 2025: Partnerships with global players expanded availability of next-generation androgen inhibitors amid rising geriatric populations.
Key Mergers and Acquisitions (2025):
✅ Johnson & Johnson acquires Halda Therapeutics: In November 2025, J&J acquired the clinical-stage biotech for $3.05 billion to strengthen its prostate cancer offerings with novel targeted candidates.
✅ Bristol Myers Squibb acquires Philochem asset: In June 2025, BMS expanded its radiopharmaceutical portfolio by acquiring OncoACP3 for up to $1.3 billion, targeting advanced prostate cancer.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=prostate-cancer-treatment-market?sindhuri
(Purchase 2 or more Reports and get 50% Discount)

Market Segmentation Analysis:
-By Therapy Type: Radioligand Therapy Leads with Dominant Share
The Radioligand Therapy segment commands the largest and fastest-growing market share, driven by precision targeting of PSMA-expressing cells in metastatic castration-resistant prostate cancer, minimizing damage to healthy tissue and improving outcomes.
Hormone Therapy remains foundational, while Immunotherapy and Targeted Therapy are high-growth areas fueled by novel approvals.
-By Stage: Advanced/Metastatic Stages Command Largest Portion
Stage IV (metastatic) drives demand due to the need for systemic, long-term management options.
-By Distribution/Other: Hospital Settings Top with Strong Demand
Hospitals dominate for administration of complex therapies like radioligands and infusions.

Growth Drivers:
Rising Incidence and Aging Population - Increasing cases, especially in men over 50, with global new diagnoses reaching 1.57 million in 2024.
Advancements in Targeted and Radioligand Therapies - Precision options like PSMA-targeted treatments revolutionizing metastatic care.
Regulatory Approvals for Novel Drugs - Expanded indications for drugs like Pluvicto and combination regimens.
Improved Diagnostics and Early Detection - Higher screening rates leading to more treatable cases and demand for advanced options.
Strong R&D Pipeline and Investments - Focus on immunotherapy, PARP inhibitors, and next-generation hormone therapies.

Speak to Our Analyst and Get Customization in the report as per your requirements:
https://www.datamintelligence.com/customize/prostate-cancer-treatment-market?sindhuri

Regional Insights:
North America dominates the global Prostate Cancer Treatment market, holding the largest share due to high prevalence, advanced healthcare infrastructure, rapid adoption of innovative therapies, favorable reimbursement, intensive R&D, and presence of leading pharmaceutical companies driving FDA fast-track approvals.
Asia-Pacific is the fastest-growing region, propelled by rising incidence in aging populations, improving diagnostics, government investments in oncology, and expanding access to targeted treatments in emerging economies.

Key Players:
Astellas Pharma | AstraZeneca | Bayer AG | Dendreon Pharmaceuticals | Exelixis Inc. | Ferring B.V. | Johnson & Johnson (Janssen Pharmaceuticals) | Pfizer Inc. | Sumitomo Pharma Co., Ltd. | Novartis | Tolmar, Inc.

Key Highlights (Top 5 Key Players) for Prostate Cancer Treatment Market:
1. Novartis leads with Pluvicto (radioligand therapy), securing expanded approvals and establishing dominance in PSMA-targeted treatments for advanced metastatic cases.
2. Johnson & Johnson strengthens through acquisitions like Halda, enhancing its portfolio with next-generation targeted therapies alongside established drugs like Erleada and Zytiga.
3. AstraZeneca excels in combination regimens and PARP inhibitors, advancing precision oncology for hormone-resistant prostate cancer.
4. Bayer AG innovates with androgen receptor inhibitors like Nubeqa, gaining multiple indications for metastatic hormone-sensitive disease.
5. Pfizer Inc. differentiates via strong hormonal and immunotherapy pipelines, supporting long-term management and improved survival outcomes.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.